L3VLUP
ProSign in

GRFS in the 13F filings

Grifols SA · CUSIP 398438408

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
31 Mar 2025
the date the book describes
Filed
15 May 2025
latest of these filings; the earliest 12 May 2025
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
95
filed both Q4 2024 and Q1 2025; 3 listed it in both
Shares listed
24,989,236
combined, among listed positions
Reported value
$178m
combined, at the quarter end

Among the 95 comparable managers: 1 buyer (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was +103,106.

Managers listing GRFS in Q1 2025

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Capital World Investors21,522,236$153munder 0.1%Added+388,00612 May 2025 (the filing on sec.gov)
Harris Associates LP3,439,000$24munder 0.1%Trimmed-284,90015 May 2025 (the filing on sec.gov)
Farallon Capital Management LLC28,000$199kunder 0.1%Held015 May 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q4 2024 to Q1 2025, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
6 in Q3 2024 to 1 in Q2 2026

Tracked managers listing it, at least.

0510152014201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
GRFS by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20139$944mn.a.n.a.
Q3 20137$993mn.a.n.a.
Q4 201311$1.3bnn.a.n.a.
Q1 201412$1.4bnn.a.n.a.
Q2 201413$1.2bnn.a.n.a.
Q3 20148$806mn.a.n.a.
Q4 20146$907mn.a.n.a.
Q1 201510$952mn.a.n.a.
Q2 20159$811mn.a.n.a.
Q3 20157$620mn.a.n.a.
Q4 201510$776mn.a.n.a.
Q1 201611$814mn.a.n.a.
Q2 201610$1.0bnn.a.n.a.
Q3 20169$913mn.a.n.a.
Q4 201610$984mn.a.n.a.
Q1 20178$1.1bnn.a.n.a.
Q2 20177$1.1bnn.a.n.a.
Q3 20179$1.1bnn.a.n.a.
Q4 20177$1.1bnn.a.n.a.
Q1 20187$833mn.a.n.a.
Q2 20188$692mn.a.n.a.
Q3 20187$516mn.a.n.a.
Q4 20187$223mn.a.n.a.
Q1 20198$281mn.a.n.a.
Q2 20198$276mn.a.n.a.
Q3 201913$346mn.a.n.a.
Q4 201911$476mn.a.n.a.
Q1 202012$476mn.a.n.a.
Q2 20209$433mn.a.n.a.
Q3 20208$472mn.a.n.a.
Q4 20207$477mn.a.n.a.
Q1 20217$471mn.a.n.a.
Q2 20216$442mn.a.n.a.
Q3 20216$357mn.a.n.a.
Q4 20215$301mn.a.n.a.
Q1 20224$281mn.a.n.a.
Q2 20225$406mn.a.n.a.
Q3 20224$162mn.a.n.a.
Q4 20224$304mn.a.n.a.
Q1 20234$294mn.a.n.a.
Q2 20235$391mn.a.n.a.
Q3 20235$404mn.a.n.a.
Q4 20235$510m31
Q1 20245$266m41
Q2 20245$249m31
Q3 20246$320m31
Q4 20243$185m12
Q1 20253$178m11
Q2 20255$341m31
Q3 20254$290m21
Q4 20253$240m57
Q1 20263$199m39
Q2 20261$162m610

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

GRFS and LLY →GRFS and JNJ →GRFS and VRTX →Choose a stock to compare with GRFS →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own GRFS, latest filings →Back to the 13F Explorer →